TABLE 4.
Isolate code(s) | Region(s) and date(s) (mo, yr) of isolation | STa | PCR serogroups | AscIb | ApaIc | inlA typed | SSI-1e | actAf (268 bp) |
---|---|---|---|---|---|---|---|---|
ER 3, ER 5 | B (9, 2007) | 2 | 4b, 4d, 4e | SOM1, SOM2 | SOM1, SOM2 | 2 | − | − |
ER 101 | B (9, 2007) | 4 | 4b, 4d, 4e | SOM3 | SOM3 | 2 | − | − |
E 14 | A (6, 2007) | 1 | 4b, 4d, 4e | SOM4 | SOM4 | 2 | − | − |
ER 99 | B (9, 2007) | 6 | 4b, 4d, 4e | SOM5 | SOM5 | 2 | − | + |
ER 87, ER 96 | B (9, 2007); B (12, 2007) | 517 | 4b, 4d, 4e | SOM8 | SOM8 | 2 | + | + |
ER 1, ER 13 | B (9, 2007) | 59 | 1/2b, 3b | SOM6, SOM7 | SOM6, SOM7 | 2 | − | + |
E 34, E 35, E 38, ER 41, ER 58, ER 111 | B (6, 2007); A, B (10, 2007); A (11, 2007) | 37 | 1/2a, 3a | SOM9 | SOM9 | 1 | − | − |
ER 29 | A (9, 2007) | 120 | 1/2a, 3a | SOM10 | SOM10 | 3 | + | − |
ER 137 | B (3, 2008) | 7 | 1/2a, 3a | SOM11 | SOM11 | 5 | + | − |
ER 75 | B (11, 2007) | 26 | 1/2a, 3a | SOM12 | SOM12 | 4 | + | − |
ER 173 | A (8, 2008) | 177 | 1/2a, 3a | SOM13 | SOM13 | 5 | − | − |
ER 54 | B (10, 2007) | 89 | 1/2a, 3a | SOM14 | SOM14 | 1 | − | + |
ER 98 | B (9, 2007) | 21 | 1/2a, 3a | SOM15 | SOM15 | 3 | − | + |
ER 132, ER 169 | B (3, 2008); A (8, 2008) | 91 | 1/2a, 3a | SOM16, SOM17 | SOM16, SOM17 | 3 | − | − |
ER 21, ER 25, ER 67 | A (9, 2007); A (11, 2007) | 101 | 1/2a, 3a | SOM18 | SOM18 | 6 | − | + |
ER 28 | A (9, 2007) | 20 | 1/2a, 3a | SOM19 | SOM19 | 1 | − | − |
ST, MLST sequence type.
AscI, PFGE type after restriction digest with the enzyme AscI.
ApaI, PFGE type after restriction digestion with the enzyme ApaI.
inlA, PCR restriction fragment length polymorphism (RFLP) type for the detection of point mutations in the 733-bp fragment of the inlA gene; RFLP types 1 and 4 with truncation in inlA gene.
Presence or absence of SSI-1 (stress survival islet 1), in L. monocytogenes intergenic region lmo0443–lmo0449.
Polymorphism in the actA gene, producing a fragment of 268 bp instead of the expected 385 bp.